Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Boston Medical Group vs Oak

Boston Medical Group
Graded #279

Lower grade

vs+14.000000000000007
Oak
Graded #42

Higher grade

The verdict

Oak takes it — 75.9/100 to 61.9/100.

Oak grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The cheapest published prices on the board, sold as a package with no membership fee.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOak +42
54
96
Dose & formulationOak +10
52
62
Clinical oversightBoston Medical Group +23
89
66
Labs & monitoringOak +5
53
58
FulfillmentOak +23
65
88
Contract termsOak +33
55
88
Boston Medical Group · left barOak · right bar

The numbers

MetricBoston Medical GroupOak
WeighScore61.9/10075.9/100
GradeCC
Scorecard rank#279#42
Semaglutide$199/mo (starting strength, rising with dose, compounded)From $119/mo
TirzepatideNot disclosedFrom $185/mo
Coverage7 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Boston Medical Group

Graded #279 · C

Strengths

  • An established medical group with a defined 12-week programme rather than an open-ended subscription
  • The price range and the 12-week total are both published, once you reach the costs page
  • Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight

Where it loses points

  • The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
  • The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
  • The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
  • Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Oak

Graded #42 · C

Strengths

  • Lowest published prices here — semaglutide from $119/mo, tirzepatide from $185/mo
  • One price across every dosage, so titrating up costs no more
  • No membership or subscription fee, and free shipping
  • All 50 states, offered in Spanish as well as English

Where it loses points

  • Same-day approval with no video call means very little clinical contact before a prescription
  • No published lab or monitoring programme
  • Injection only, and no brand-name lane
  • Sold as packages, so re-ordering is on you

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard